235 related articles for article (PubMed ID: 8057660)
1. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.
Ghaddar HM; Plunkett W; Kantarjian HM; Pierce S; Freireich EJ; Keating MJ; Estey EH
Leukemia; 1994 Aug; 8(8):1269-74. PubMed ID: 8057660
[TBL] [Abstract][Full Text] [Related]
2. Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia.
Ghaddar HM; Pierce S; Kantarjian HM; Freireich EJ; Keating MJ; Estey EH
Leuk Lymphoma; 1996 Jun; 22(1-2):71-6. PubMed ID: 8724530
[TBL] [Abstract][Full Text] [Related]
3. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
Jehn U; Heinemann V; Wilmanns W
Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
[TBL] [Abstract][Full Text] [Related]
4. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
[TBL] [Abstract][Full Text] [Related]
5. Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia.
Estey EH; Keating MJ; McCredie KB; Freireich EJ; Plunkett W
Leukemia; 1990 Feb; 4(2):95-9. PubMed ID: 2304361
[TBL] [Abstract][Full Text] [Related]
6. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
[TBL] [Abstract][Full Text] [Related]
7. High rate of long-term survival in adult acute leukemia following ten-day chemotherapy (OAP) induction. Maintenance with chemotherapy or chemotherapy plus BCG vaccine.
Hewlett JS; Chen T; Balcerzak SP; Gutterman JU; Costanzi JJ; Amare M
Arch Intern Med; 1985 Jun; 145(6):1006-12. PubMed ID: 3890786
[TBL] [Abstract][Full Text] [Related]
8. Double intensification with amsacrine/high dose ara-C and high dose chemotherapy with autologous bone marrow transplantation produces durable remissions in acute myelogenous leukemia.
Spinolo JA; Dicke KA; Horwitz LJ; Jagannath S; Zander AR; Auber ML; Spitzer G
Bone Marrow Transplant; 1990 Feb; 5(2):111-8. PubMed ID: 1690035
[TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence.
MacCallum PK; Davis CL; Rohatiner AZ; Lim J; Gupta RK; Whelan JS; Price CG; Evans ML; Amess JA; Leahy M
Leukemia; 1993 Oct; 7(10):1496-9. PubMed ID: 8412309
[TBL] [Abstract][Full Text] [Related]
10. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
11. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
12. A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia.
Keating MJ; Gehan EA; Smith TL; Estey EH; Walters RS; Kantarjian HM; McCredie KB; Freireich EJ
J Clin Oncol; 1987 May; 5(5):710-21. PubMed ID: 3553435
[TBL] [Abstract][Full Text] [Related]
13. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
Plunkett W; Nowak B; Keating MJ
Cancer Treat Rep; 1987 May; 71(5):479-83. PubMed ID: 3567973
[TBL] [Abstract][Full Text] [Related]
14. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
Jehn U; Heinemann V
Haematol Blood Transfus; 1990; 33():333-8. PubMed ID: 1691134
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16.
Marlton P; Keating M; Kantarjian H; Pierce S; O'Brien S; Freireich EJ; Estey E
Leukemia; 1995 Jun; 9(6):965-71. PubMed ID: 7596186
[TBL] [Abstract][Full Text] [Related]
16. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
[TBL] [Abstract][Full Text] [Related]
19. Short term therapy (STT) for acute myelogenous leukaemia (AML).
Rohatiner AZ; Battista R; Bassan R; Love S; Oza AM; Whelan JS; Lim J; Buelli M; Viero P; D'Emillio A
Leukemia; 1992; 6 Suppl 2():85-8. PubMed ID: 1578952
[TBL] [Abstract][Full Text] [Related]
20. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia.
Boos J; Hohenlöchter B; Schulze-Westhoff P; Schiller M; Zimmermann M; Creutzig U; Ritter J; Jurgens H
Med Pediatr Oncol; 1996 Jun; 26(6):397-404. PubMed ID: 8614376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
